Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK)... Read more.
Seeing Machines to unveil 3D Cabin Perception Mapping at CES2026
Pioneering interior sensing technology to advance automotive safety and customer experience CANBERRA, Australia, Jan. 5, 2026 /PRNewswire/ — Seeing Machines,... Read more.
Arbe Combines Market-Leading Radar Solution with Powerful NVIDIA AI Computing, Creating Advanced Platform for AI-based Driving
For the First Time at CES 2026, Arbe will Showcase its Automotive-grade Radar System, Ready for Integration with Complete Perception Stacks TEL AVIV, Israel, Jan.... Read more.
A2Z Cust2Mate Deepens Migros Ticaret A.Ş. Relationship to Transform In-Store Shopping with Smart Carts
TORONTO, Jan. 5, 2026 /PRNewswire/ – A2Z Cust2Mate Solutions Corp (NASDAQ: AZ), a global leader in smart retail technology, announces that its smart carts... Read more.
COOLFLY to Debut the Aura Smart Bird Feeder at CES 2026
A design-led, modular, and socially connected reinvention of the smart feeder category LAS VEGAS, Jan. 5, 2026 /PRNewswire/ — COOLFLY, the smart-outdoor technology... Read more.
IntBot to Debut First-Ever Unmanned CES Booth Run by a Robot; Humanoid “Nylo” Takes the Floor Solo
LAS VEGAS, Jan. 5, 2026 /PRNewswire/ — CES 2026 — IntBot, the social robotics company with an active commercial fleet deployed in hospitality environments,... Read more.
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ —... Read more.
RedHill’s RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology... Read more.
NaaS Technology Inc. to Hold Extraordinary General Meeting on January 23, 2026
BEIJING, Jan. 5, 2025 /PRNewswire/ — NaaS Technology Inc. (Nasdaq: NAAS) (“NaaS” or the “Company”), the first U.S.-listed EV charging... Read more.
VIPRE Security Group: AI-Native Malware, Deepfake Fraud-as-a-Service, and IoT Exploits to Drive Enterprise Risk in 2026 — With Global AI Regulation Accelerating the Urgency of Human-Centric Security Training
LONDON, Jan. 5, 2026 /PRNewswire/ — 2025 saw a surge in AI-enabled cyberthreats as adversaries weaponised generative models to produce polymorphic malware,... Read more.